Last update 08 May 2025

PF-08046031

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Target
CD228 x Tubulin
Action
inhibitors
Mechanism
CD228 inhibitors(Melanotransferrin inhibitors), Tubulin inhibitors
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication
Locally Advanced MelanomaMetastatic melanomaMelanoma
Inactive Indication-
Originator Organization
Pfizer Inc.Pfizer Inc.
Active Organization
Pfizer Inc.Pfizer Inc.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC11H22N4O4
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N
CAS Registry159858-33-0
View All Structures (2)
Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with PF-08046031
NCT06799533
/ Not yet recruitingPhase 1
An Open-Label Phase 1 Study to Investigate PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors
100 Clinical Results associated with PF-08046031
Login to view more data
100 Translational Medicine associated with PF-08046031
Login to view more data
100 Patents (Medical) associated with PF-08046031
Login to view more data
100 Deals associated with PF-08046031
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced MelanomaPhase 1-
Pfizer Inc.Pfizer Inc.
18 Apr 2025
Metastatic melanomaPhase 1-
Pfizer Inc.Pfizer Inc.
18 Apr 2025
MelanomaPreclinical
United States
Pfizer Inc.Pfizer Inc.
28 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
PF-08046031 (AACR2025)
Not Applicable
Melanoma
CD228-positive
-
mbekmrnjms(avwnjdqdlt) = vwqzffoxzo tsmwgsgpfz (ksqnkdceua )
-
28 Apr 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free